Skip to main content

Pruvanserin









Pruvanserin


From Wikipedia, the free encyclopedia

Jump to navigation
Jump to search

























































Pruvanserin
Pruvanserin.png
Clinical data
Routes of
administration		 Oral
ATC code
  • none
Legal status
Legal status

  • In general: uncontrolled
Identifiers
CAS Number

  • 443144-26-1
    443144-27-2 (hydrochloride)

PubChem CID
  • 6433122
ChemSpider
  • 4938310
UNII
  • UL09X1D9EM
ChEMBL
  • ChEMBL1215661
Chemical and physical data
Formula
C22H21FN4O
Molar mass 376.43 g/mol
3D model (JSmol)
  • Interactive image

Pruvanserin (EMD-281,014, LY-2,422,347) is a selective 5-HT2A receptor antagonist which was under development by Eli Lilly and Company for the treatment of insomnia.[1][2] It was in phase II clinical trials in 2008 but appears to have been discontinued as it is no longer in the company's development pipeline.[3][4] In addition to its sleep-improving properties,[5][6] pruvanserin has also been shown to have antidepressant, anxiolytic, and working memory-enhancing effects in animal studies.[7][8][9]



See also[edit]



  • Eplivanserin

  • Pimavanserin

  • Volinanserin



References[edit]





  1. ^ Bartoszyk GD, van Amsterdam C, Böttcher H, Seyfried CA (July 2003). "EMD 281014, a new selective serotonin 5-HT2A receptor antagonist". European Journal of Pharmacology. 473 (2–3): 229–30. doi:10.1016/S0014-2999(03)01992-7. PMID 12892843..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  2. ^ Teegarden BR, Al Shamma H, Xiong Y (2008). "5-HT(2A) inverse-agonists for the treatment of insomnia". Current Topics in Medicinal Chemistry. 8 (11): 969–76. doi:10.2174/156802608784936700. PMID 18673166.


  3. ^ "Efficacy Study of LY2422347 to Treat Insomnia - Full Text View - ClinicalTrials.gov".


  4. ^ "Eli Lilly and Company » Research Pipeline".


  5. ^ Monti JM, Jantos H (September 2006). "Effects of activation and blockade of 5-HT2A/2C receptors in the dorsal raphe nucleus on sleep and waking in the rat". Progress in Neuro-psychopharmacology & Biological Psychiatry. 30 (7): 1189–95. doi:10.1016/j.pnpbp.2006.02.013. PMID 16713054.


  6. ^ Monti JM, Jantos H (December 2006). "Effects of the serotonin 5-HT2A/2C receptor agonist DOI and of the selective 5-HT2A or 5-HT2C receptor antagonists EMD 281014 and SB-243213, respectively, on sleep and waking in the rat". European Journal of Pharmacology. 553 (1–3): 163–70. doi:10.1016/j.ejphar.2006.09.027. PMID 17059817.


  7. ^ Patel JG, Bartoszyk GD, Edwards E, Ashby CR (April 2004). "The highly selective 5-hydroxytryptamine (5-HT)2A receptor antagonist, EMD 281014, significantly increases swimming and decreases immobility in male congenital learned helpless rats in the forced swim test". Synapse. 52 (1): 73–5. doi:10.1002/syn.10308. PMID 14755634.


  8. ^ Adamec R, Creamer K, Bartoszyk GD, Burton P (November 2004). "Prophylactic and therapeutic effects of acute systemic injections of EMD 281014, a selective serotonin 2A receptor antagonist on anxiety induced by predator stress in rats". European Journal of Pharmacology. 504 (1–2): 79–96. doi:10.1016/j.ejphar.2004.09.017. PMID 15507224.


  9. ^ Terry AV, Buccafusco JJ, Bartoszyk GD (June 2005). "Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys". Psychopharmacology. 179 (4): 725–32. doi:10.1007/s00213-004-2114-1. PMID 15619109.













Retrieved from "https://en.wikipedia.org/w/index.php?title=Pruvanserin&oldid=862767489"





Navigation menu

























(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"1.056","walltime":"1.245","ppvisitednodes":{"value":4511,"limit":1000000},"ppgeneratednodes":{"value":0,"limit":1500000},"postexpandincludesize":{"value":339242,"limit":2097152},"templateargumentsize":{"value":2096,"limit":2097152},"expansiondepth":{"value":14,"limit":40},"expensivefunctioncount":{"value":2,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":27643,"limit":5000000},"entityaccesscount":{"value":2,"limit":400},"timingprofile":["100.00% 781.888 1 -total"," 56.64% 442.860 1 Template:Drugbox"," 38.18% 298.526 1 Template:Infobox"," 27.72% 216.728 1 Template:Reflist"," 24.11% 188.537 21 Template:Navbox"," 22.96% 179.528 7 Template:Cite_journal"," 10.94% 85.514 16 Template:Unbulleted_list"," 9.24% 72.241 1 Template:Serotonergics"," 5.20% 40.644 1 Template:Hypnotics"," 4.80% 37.525 1 Template:Infobox_drug/chemical_formula"]},"scribunto":{"limitreport-timeusage":{"value":"0.340","limit":"10.000"},"limitreport-memusage":{"value":5064999,"limit":52428800}},"cachereport":{"origin":"mw1246","timestamp":"20181216184948","ttl":1900800,"transientcontent":false}}});});{"@context":"https://schema.org","@type":"Article","name":"Pruvanserin","url":"https://en.wikipedia.org/wiki/Pruvanserin","sameAs":"http://www.wikidata.org/entity/Q7253203","mainEntity":"http://www.wikidata.org/entity/Q7253203","author":{"@type":"Organization","name":"Contributors to Wikimedia projects"},"publisher":{"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":{"@type":"ImageObject","url":"https://www.wikimedia.org/static/images/wmf-hor-googpub.png"}},"datePublished":"2010-03-30T01:26:55Z","dateModified":"2018-10-06T15:30:37Z","image":"https://upload.wikimedia.org/wikipedia/commons/8/83/Pruvanserin.png","headline":"chemical compound"}(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgBackendResponseTime":103,"wgHostname":"mw1323"});});
-

Popular posts from this blog

Full-time equivalent

Image
Full-time equivalent From Wikipedia, the free encyclopedia Jump to navigation Jump to search Full-time equivalent ( FTE ) or whole time equivalent ( WTE ) is a unit that indicates the workload of an employed person (or student) in a way that makes workloads or class loads comparable [1] across various contexts. FTE is often used to measure a worker's or student's involvement in a project, or to track cost reductions in an organization. An FTE of 1.0 is equivalent to a full-time worker or student, while an FTE of 0.5 signals half of a full work or school load. [2] Contents 1 U.S. Federal Government 2 In education 2.1 Example 3 Notes 4 References U.S. Federal Government [ edit ] In the U.S. Federal Government, FTE is defined by the Government Accountability Office (GAO) as the number of total hours worked divided by the maximum number of compensable hours in a full-time schedule as
Read more

Bicuculline

Image
Bicuculline From Wikipedia, the free encyclopedia Jump to navigation Jump to search Bicuculline Clinical data ATC code none Identifiers IUPAC name (6 R )-​6-​[(5 S )-​6-​methyl-​5,​6,​7,​8-​tetrahydro​[1,3]dioxolo​[4,5- g ]​isoquinolin-​5-​yl]​furo[3,4- e ]​[1,3]​benzodioxol-​8(6 H )-​one CAS Number 485-49-4   Y PubChem CID 10237 IUPHAR/BPS 2312 ChemSpider 9820   Y UNII Y37615DVKC ChEBI CHEBI:3092   N ChEMBL ChEMBL417990   N ECHA InfoCard 100.006.927 Chemical and physical data Formula C 20 H 17 N O 6 Molar mass 367.352 g/mol 3D model (JSmol) Interactive image Melting point 215 °C (419 °F) SMILES O=C1O[C@H](c3c1c2OCOc2cc3)[C@@H]5c4cc6OCOc6cc4CCN5C InChI InChI=1S/C20H17NO6/c1-21-5-4-10-6-14-15(25-8-24-14)7-12(10)17(21)18-11-2-3-13-19(26-9-23-13)16(11)20(22)27-18/h2-3,6-7,17-18H,4-5,8-9H2,1H3/t17-,18+/m0/s1   Y Key:IYGYMKDQCDOMRE-ZWKOTPCHSA-N
Read more

さくらももこ

Image
さくら ももこ 本名 非公開 [1] 生誕 ( 1965-05-08 ) 1965年5月8日 日本・静岡県清水市 （現・静岡市清水区） 死没 ( 2018-08-15 ) 2018年8月15日（53歳没） 日本・東京都目黒区 国籍 日本 職業 漫画家 エッセイスト 作詞家 活動期間 1984年 - 2018年 ジャンル 少女漫画 青年漫画 児童漫画 代表作 『ちびまる子ちゃん』 『コジコジ』 受賞 1989年：第13回講談社漫画賞少女部門 （『ちびまる子ちゃん』） 1990年：第32回日本レコード大賞 （『おどるポンポコリン』作詞） 公式サイト さくらプロダクション テンプレートを表示 さくら ももこ （1965年5月8日 - 2018年8月15日 [2] ）は、日本の漫画家、エッセイスト、作詞家、脚本家。また、自身の少女時代をモデルとした代表作のコミック『ちびまる子ちゃん』の主人公の名前でもある。静岡県清水市（現・静岡市清水区）出身。血液型はA型。身長159cm。一男の母親。 代表作のコミック『ちびまる子ちゃん』の単行本の売上は累計3000万部を超える。また、エッセイストとしても独特の視点と語り口で人気が高く、初期エッセイ集三部作『もものかんづめ』『さるのこしかけ』『たいのおかしら』はいずれもミリオンセラーを記録。 目次 1 経歴 2 人物・交遊関係 3 主な作品 3.1 漫画 3.2 エッセイ 3.3 作詞 3.4 詩集 3.5 雑誌・ムック本 3.6 翻訳 3.7 絵本、ドラマ脚本他 3.8 ラジオ出演 3.9 その他 4 関係人物 4.1 アシスタント 4.2 さくらももこを演じた人物 5 脚注 5.1 注釈 5.2 出典 6 外部リンク 経歴 年譜形式の経歴は推奨されていません 。人物の伝記は流れのあるまとまった文章で記述し、年譜は補助的な使用にとどめてください。 （ 2018年8月 ） 清水市立（当時）入江小学校
Read more